Scholar Rock (SRRK)
Develops anti-myostatin antibodies for spinal muscular atrophy and other neuromuscular diseases.
$51.17
vs last close+3.01 (+6.25%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 114.62% | 139.59M shares | |
|---|---|---|---|
| 317 holders · as of Jun 30, 2026 | |||
| Insiders | 9.96% | 12.13M shares | |
| 20 holders · as of Jul 6, 2026 | |||
| Strategic holders | 8.89% | 10.83M shares | |
| 1 holder · as of Feb 6, 2026 | |||
| Adds to | 133.47% | ||
121.79M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 133.47%; nothing is left for Other.
13F, as of Jun 30, 2026
317 holders · 139.59M shares · 59 new positions · 191 increased · 83 reduced · 27 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 18.00M | 14.78% | +752.1K | Aug 13, 2026 |
| Siren, L.L.C. | 9.58M | 7.86% | −1.25M | Aug 13, 2026 |
| BlackRock, Inc. | 9.49M | 7.80% | +2.02M | Aug 7, 2026 |
| Samsara Biocapital, LLC | 6.90M | 5.66% | 0 | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 6.79M | 5.58% | +588.2K | Aug 14, 2026 |
| Wellington Management Group LLP | 6.73M | 5.52% | +9.4K | Aug 14, 2026 |
| Orbis Allan Gray Ltd | 5.93M | 4.87% | +1.75M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 4.77M | 3.91% | +876.5K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.00% | 14.11M | 13G | Feb 12, 2025 |
| Invus Public Equities, L.P. | 11.40% | 10.83M | 13G | Feb 12, 2025 |
| Redmile Group, LLC | 7.60% | 9.07M | 13G | May 15, 2026 |
| Srinivas Akkarajuincl. Samsara Opportunity Fund GP, LLC, Samsara Opportunity Fund, L.P. +2 more | 7.20% | 6.99M | 13D | Oct 7, 2025 |
| Wellington Management Group LLP | 5.60% | 5.76M | 13G | Feb 10, 2026 |
| T. Rowe Price Associates, Inc. | 5.40% | 6.21M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 1, 2026 | Katie Pengdirector | Sale · 3 lots | 5,446 | $53.88 | 34,301 |
| Jul 1, 2026 | Joshua Reeddirector | Sale · 2 lots | 3,053 | $53.74 | 19,518 |
| Jul 1, 2026 | Kristina Burowdirector | Sale · 2 lots | 3,053 | $53.74 | 114,657 |
| Jul 1, 2026 | Michael Gilmandirector | Sale · 3 lots | 2,544 | $53.87 | 59,511 |
| Jul 1, 2026 | Jeffrey S. Flierdirector | Sale · 3 lots | 3,053 | $53.88 | 27,856 |
| Apr 16, 2026 | David Hallaldirector, officer: Chief Executive Officer | Sale | 30,615 | $49.57 | 1,639,034 |
| Apr 16, 2026 | Vikas Sinhaofficer: Chief Financial Officer | Sale | 10,410 | $49.57 | 619,856 |
| Apr 16, 2026 | Akshay Vaishnawdirector, officer: President of R&D | Sale | 12,246 | $49.57 | 630,542 |
| Apr 16, 2026 | Keith Woodsofficer: Chief Operating Officer | Sale | 10,220 | $49.57 | 620,055 |
| Feb 23, 2026 | Mo Qatananiofficer: CHIEF SCIENTIFIC OFFICER | Sale · 3 lots | 8,484 | $47.07 | 98,445 |
House and Senate disclosures
Not reported.